53234-55-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Cyanopyridine-2-carboxylic acid is used as a pharmaceutical intermediate for the synthesis of various drugs and drug candidates. Its unique chemical structure allows it to be a key component in the development of new medications.
Used in Biochemical Research:
In the field of biochemistry, 5-Cyanopyridine-2-carboxylic acid is utilized as an inhibitor of DBM (Dopamine β-monooxygenase) from bovine adrenal medulla. This application aids in studying the enzyme's role in the biosynthesis of catecholamines, which are essential neurotransmitters and hormones.
Used in Drug Development:
5-Cyanopyridine-2-carboxylic acid is also used in the development of benzoylthiophenes, which are allosteric enhancers (AE) of agonist activity at the A1 adenosine receptor. This application is significant for the treatment of various conditions, including neurodegenerative diseases and cardiovascular disorders, by modulating the adenosine receptor's function.

InChI:InChI=1/C7H4N2O2/c8-3-5-1-2-6(7(10)11)9-4-5/h1-2,4H,(H,10,11)

Upstream product

• 33252-28-7 6-chloronicotinonitrile 
• 201230-82-2 carbon monoxide 
• 29682-15-3 methyl 5-bromopicolinate 

Downstream Products

• 144412-34-0 (R,S)-methyl phenoxy>acetate 
• 144411-91-6 methyl phenoxy>acetate 
• 1026510-91-7 (4-{2-[(5-Thiocarbamoyl-pyridine-2-carbonyl)-amino]-acetyl}-phenoxy)-acetic acid methyl ester 
• 745757-99-7 (4-{2-[(5-Carbamimidoyl-pyridine-2-carbonyl)-amino]-acetyl}-phenoxy)-acetic acid methyl ester 
• 1026281-70-8 (4-{2-[(5-Methylsulfanylcarbonimidoyl-pyridine-2-carbonyl)-amino]-acetyl}-phenoxy)-acetic acid methyl ester 
• 1310877-09-8 (S)-N-(3-(2-amino-4-(difluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide 
• 1415208-85-3 tert-butyl ((4aR,7aR)-7a-(5-(5-cyanopicolinamido)-2-fluorophenyl)-4a,5,6,7a-tetrahydro-4H-furo[2,3-d][1,3]thiazin-2-yl)carbamate 
• 1352416-78-4 N-{3-[(2R,3R)-5-amino-3-methyl-2-(trifluoromethyl)-3,6-dihydro-2H-1,4-oxazin-3-yl]-4-fluorophenyl}-5-cyanopyridine-2-carboxamide 
• 1262856-22-3 5-bromopyridine-2-carboxylic acid [3-((S)-3-amino-5-difluoromethyl-2,5,6,7-tetrahydro-[1,4]oxazepin-5-yl)-4-fluoro-phenyl]-amide hydrochloride 
• 1432511-79-9 N-(3-((4S,6S)-2-amino-4-(fluoromethyl)-6-(trifluoromethyl)-5,6-dihydro-4H-1,3-oxazin-4-yl)-4-fluorophenyl)-5-cyanopicolinamide 
• 1402412-80-9 5-cyano-pyridine-2-carboxylic acid [3-((4S,5R)-2-amino-5-fluoro-4-fluoromethyl-5,6-dihydro-4H-[1,3]oxazin-4-yl)-4-fluoro-phenyl]-amide 
• 1416797-67-5 (S)-N₂-((3-fluoropyridin-2-yl)(4-(trifluoromethyl)phenyl)-methyl)pyridine-2,5-dicarboxamide 

Relevant academic research and scientific papers

HALOGEN-ALKYL-1,3 OXAZINES AS BACE1 AND/OR BACE2 INHIBITORS

The present invention provides compounds of formula (I) having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

SYNTHESIS OF BACE1 INHIBITORS

The present invention provides a one step carbonylation of a compound of formula II in the presence of water to afford a compound of formula (I), useful in processes to manufacture BACE inhibitors.

FUSED AMINODIHYDROTHIAZINE DERIVATIVES

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine;A is CH or N;Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or —C≡N; and pharmaceutically acceptable salts thereof; which compound has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.

FUSED AMINODIHYDROTHIAZINE DERIVATIVES USEFUL AS BACE INHIBITORS

The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein X is hydrogen or fluorine; A is CH or N; Y is methyl, ethyl, monofluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl, methoxy, ethoxy, methoxymethyl or -C≡N; and pharmaceutically acceptable salts thereof; which compound has an Αβ production inhibitory effect or a BACEl inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Αβ and typified by Alzheimer-type dementia.

FUSED AMINODIHYDROPYRIMIDONE DERIVATIVES

A compound represented by the general formula (I) or pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1, R2 and Rx are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Abeta production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Abeta and typified by Alzheimer-type dementia.

FUSED AMINODIHYDRO-OXAZINE DERIVATIVES

A compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is -NReCO- or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer-type dementia.